Opsens Inc T.OPS

Reminder for those who are tempted to sell

[Nadia6519]

“Opsens is making major strides towards commercializing its transcatheter aortic valve replacement (TAVR) guidewire, the SavvyWire. The TAVR market is expected to grow at a 15% CAGR through 2025 (with a TAM of $8B+) given the time/cost savings and efficacy benefits vs. traditional surgical procedures. The SavvyWire is the only guidewire for aortic valve replacement that can provide continuous pressure measurement and as such we assume it will achieve 10% market share by 2025 (generating $43M in sales). OPS recently completed a 20-patient clinical trial and has filed for approvals with Health Canada and the U.S. FDA. We are expecting Health Canada approval by H1/22, U.S. FDA approval in Q3/22 and European CE certification subsequently.

“Edwards Lifesciences (EW:NYSE) is the largest aortic valve manufacturer in the world but does not produce a TAVR guidewire. Of the major manufacturers that do produce guidewires – Boston Scientific and Medtronic, neither has a wire that can be used to perform continuous pressure measurement. We believe this gap in the market presents a massive opportunity for Opsens to carve out market share or get acquired by a large-cap medical device company.”

From M. Partners, Investment banking firm, Toronto, Published in Jan. 2022

[88guy88]

Stop selling and relax....we all know that you are a shareholder....its gonna do what its gonna do and nothing you post is gonna change that.....it tested the $1.90 which is normal and then it bumps back up again which is normal....and likely at some point today or next week its gonna go test that $1.90 again and slip below that......its just a predetermined market menatality